Drug Profile
SL 052
Alternative Names: Nanoparticle formulation of SL052 (for IV administration) - Quest PharmaTech; Photodynamic cancer therapy (SL052) - Quest PharmaTech; SL 052 PDT; SL052Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Quest PharmaTech
- Developer BC Cancer Agency; National Research Council Canada; Quest PharmaTech; University of Alberta
- Class Antineoplastics
- Mechanism of Action Immunostimulants; Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal cancer; Lung cancer; Prostate cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Prostate-cancer in Canada (Intra-arterial, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-cancer in Canada (IV, Injection)
- 25 Jul 2013 SL 052 is still in phase I trials for Prostate cancer in Canada